San Francisco, CA--January 13, 2016 Verseon (AIM: VSN). Dr. David Kita, Verseon’s co-founder and Vice President of Research and Development, presented preclinical data on the company’s new class of anti-coagulants at the 8th annual Biotech Showcase yesterday - January 12th. Kita’s presentation included recently obtained data on a number of drug candidates in this new class that demonstrates continuing and steady progress in Verseon’s anticoagulation program.
Verseon is a technology-based pharmaceutical company that uses their own proprietary and patented computational drug discovery platform to research and develop novel drugs and drug therapies for unmet medical needs.
The Company’s new class of oral, highly selective, direct thrombin inhibitors have been proven in preclinical efficacy studies and also show pharmacokinetic profiles suitable for oral dosing. Verseon’s compounds demonstrate reduced risk of major bleeding relative to current novel oral anticoagulants (NOACs).
Kita said, “the data we have obtained in our anticoagulant program represents comprehensive preclinical, scientific evidence that Verseon’s compounds have lower bleeding risk than conventional therapies with equivalent or better therapeutic potential. This data will form an important part of our upcoming IND (Investigational New Drug) filings for this program.”
